Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

14.37 -0.27 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 197,811
Open 14.63
Bid (Size) 14.37 (3,600)
Ask (Size) 14.41 (400)
Prev. Close 14.64
Today's Range 14.19 - 14.79
52wk Range 4.090 - 15.34
Shares Outstanding 21,055,392
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Reports Mixed Q4 and Full-Year 2025 Results ↗
Enanta Pharmaceuticals reported mixed Q4 2025 results, missing revenue but beating EPS estimates. The biotech firm highlighted strong progress in its RSV and immunology drug pipeline. 
Via Chartmill
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+157.1%
+157.1%
1 Month
+24.8%
+24.8%
3 Month
+72.5%
+72.5%
6 Month
+80.8%
+80.8%
1 Year
+66.3%
+66.3%

More News

Read More
News headline image
Earnings Scheduled For November 17, 2025 ↗
Via Benzinga
News headline image
Enanta Pharma's Earnings: A Preview ↗
Via Benzinga
News headline image
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
Via Benzinga
News headline image
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update ↗
Via Stocktwits
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga

Frequently Asked Questions

Is Enanta Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Enanta Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Enanta Pharmaceuticals, Inc. - Common Stock trade on?
Enanta Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock is ENTA on the Nasdaq Stock Market
What is the current price of Enanta Pharmaceuticals, Inc. - Common Stock?
The current price of Enanta Pharmaceuticals, Inc. - Common Stock is 14.37
When was Enanta Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Enanta Pharmaceuticals, Inc. - Common Stock was at 12/10/25 04:00 PM ET
What is the market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock is 302.57M
How many shares of Enanta Pharmaceuticals, Inc. - Common Stock are outstanding?
Enanta Pharmaceuticals, Inc. - Common Stock has 303M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.